| 1 |
Zhu PP, Li XX, Liu JH, et al. SMARCA4-deficient undifferentiated carcinoma of the gastrointestinal tract: a clinicopathological and immunohistochemical study of nine cases [J]. Zhonghua Bing Li Xue Za Zhi, 2022,51(9): 868-874.
|
| 2 |
Wang J, Elghawy O, Kurpiel B, et al. Diagnosis and management of gastrointestinal SMARCA4-deficient undifferentiated tumors [J]. Clin J Gastroenterol, 2023,16(6): 807-814.
|
| 3 |
Duan H, Gao W, Wang L, et al. Undifferentiated colonic neoplasm with SMARCA4 germline gene mutation and loss of SMARCA4 protein expression: a case report and literature review [J]. Diagn Pathol, 2021,16(1): 30.
|
| 4 |
Yadav R, Sun L, Salyana M, et al. SMARCA4-Deficient Undifferentiated Tumor of Lung Mass-A Rare Tumor With the Rarer Occurrence of Brain Metastasis: A Case Report and Review of the Literature [J]. J Investig Med High Impact Case Rep, 2022,10: 23247096221074864.
|
| 5 |
Meda Y, Miyake H, Nagai H, et al. SMARCA4-deficient rectal carcinoma with a sarcomatoid component: a case report [J]. Clin J Gastroenterol, 2022,15(2): 419-426.
|
| 6 |
Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis [J]. BMJ, 2018,362: k3529.
|
| 7 |
Agaimy A, Daum O, Märkl B, et al. SWI/SNF complex-deficient undifferentiated/rhabdoid carcinomas of the gastrointestinal tract: A series of 13 cases highlighting mutually exclusive loss of SMARCA4 and SMARCA2 and frequent Co-inactivation of SMARCB1 and SMARCA2 [J]. Am J Surg Pathol, 2016,40(4): 544-553.
|
| 8 |
Perret R, Chalabreysse L, Watson S, et al. SMARCA4-deficient thoracic sarcomas clinicopathologic study of 30 cases with an emphasis on their nosology and differential diagnoses [J]. Am J Surg Pathol, 2019,43(4): 455-465.
|
| 9 |
Le Loarer F, Watson S, Pierron G, et al. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas [J]. Nat Genet, 2015,47(10): 1200-1205.
|
| 10 |
王泓懿. 结直肠癌肿瘤标志物的研究进展 [J/OL]. 中华临床医师杂志(电子版), 2021,15(1): 47-51.
|
| 11 |
Chang B, Sheng W, Wang L, et al. SWI/SNF complex-deficient undifferentiated carcinoma of the gastrointestinal tract: clinicopathologic study of 30 cases with an emphasis on variable morphology, immune features, and the prognostic significance of different SMARCA4 and SMARCA2 subunit deficiencies [J]. Am J Surg Pathol, 2022,46(7): 889-906.
|
| 12 |
Horton RK, Ahadi M, Gill AJ, et al. SMARCA4/SMARCA2-deficient carcinoma of the esophagus and gastroesophageal junction [J]. Am J Surg Pathol, 2021,45(3): 414-420.
|
| 13 |
Kuwamoto S, Matsushita M, Takeda K, et al. SMARCA4-deficient thoracic sarcoma: report of a case and insights into how to reach the diagnosis using limited samples and resources [J]. Hum Pathol, 2017,70: 92-97.
|
| 14 |
Meng X, Ma J, Meng N, et al. Case report: SMARCA4 (BRG1)-deficient undifferentiated carcinoma of gallbladder with genetic analysis [J]. Front Oncol, 2023,13: 1086266.
|
| 15 |
Pokhrel A, Yadav R, Manvar KK, et al. Chemotherapy and immune checkpoint Inhibitors in a case of SMARCA4-dUT: A case report and review of literature [J]. J Investig Med High Impact Case Rep, 2023,11: 23247096231176220.
|
| 16 |
Sahin IH, Akce M, Alese O, et al. Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms [J]. Br J Cancer, 2019,121(10): 809-818.
|
| 17 |
Diaz LA Jr, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study [J]. Lancet Oncol, 2022,23(5): 659-670.
|
| 18 |
栗慧慧, 林香春. 早发结直肠癌的临床特征及危险因素分析 [J/OL]. 中华临床医师杂志(电子版), 2024,18(2): 195-200.
|
| 19 |
Al-Shbool G, Krishnan Nair H. SMARCA4-deficient undifferentiated tumor: A rare malignancy with distinct clinicopathological characteristics [J]. Cureus, 2022,14(10): e30708.
|